Product Description
DNA plasmids encoding the hemagglutinin (HA), neuraminidase (NA), and M2e-NP antigen of the H5N1 avian influenza virus (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01184976)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GeneOne Life Science
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Influenza, Human|Influenza in Birds
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01184976 |
FLU-001 | P1 |
Completed |
Influenza, Human |
2012-04-01 |
2019-03-19 |
Treatments |
|
NCT01142362 |
FLU-001 | P1 |
Completed |
Influenza, Human|Influenza in Birds |
2011-11-01 |
2019-03-19 |
Recent News Events
Date |
Type |
Title |
|---|